According to the joint statement, Cipla will utilise its skills and solid India-wide network of distributors, institutions and market outreach programmes to expand access to these treatments for patients. Meanwhile, Sanofi India will continue to own, import, and manufacture its entire range of CNS products across plants in India and abroad.
